RxDoctor Payments Data

Salma Akter, MD

Cardiology · Hudson, NYNPI 1205097904

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (56.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Medtronic at 40.3% of the total.

$8,593in general payments, 2019–2025

Across 137 payments — averaging $62.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Boston Scientific$2K
  • Abbott$1K
  • Pfizer$426
  • Amgen$388
  • Novartis$195
  • plus $1K from 17 others

What the payments were for

  • Travel & lodging$4,85557%
  • Food & beverage$3,63942%
  • Education$991%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,593 in reported general payments places this provider in the 80th percentile of 112 cardiology providers in New York.

See all cardiology providers in New York

Medicare billing

Part B allowed, 2024
$99,692
Medicare patients
571
Services billed
1,504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban197$245,731
EntrestoSacubitril/Valsartan80$92,164
XareltoRivaroxaban32$48,792
Repatha SureclickEvolocumab45$45,272
Praluent PenAlirocumab27$27,052
Metoprolol Succinate462$5,790
Atorvastatin Calcium458$4,575
Ezetimibe167$3,916
Rosuvastatin Calcium175$2,889
Labetalol Hcl13$1,279
Losartan Potassium139$1,035
Nifedipine ErNifedipine44$982
Amlodipine Besylate192$946
Pravastatin Sodium76$858
Diltiazem 24hr Er (Cd)Diltiazem Hcl28$817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$426$245,731197 claims
NovartisEntresto$195$92,16480 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 112 cardiology providers in New York.

Other cardiology in Hudson

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →